Compositions and methods for treatment of severe acute respiratory syndrome (SARS)
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/215
A61K-039/395
C12P-019/34
C07H-019/00
출원번호
UP-0557479
(2004-05-20)
등록번호
US-7722886
(2010-06-14)
국제출원번호
PCT/US2004/015864
(2004-05-20)
§371/§102 date
20051121
(20051121)
국제공개번호
WO05/018535
(2005-03-03)
발명자
/ 주소
Siber, George R.
출원인 / 주소
Wyeth
대리인 / 주소
Hunton & Williams LLP
인용정보
피인용 횟수 :
0인용 특허 :
33
초록▼
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein,
Compositions and methods for treating Severe Acute Respiratory Syndrome (SARS) are disclosed herein. Inhibitors of SARS-associated inflammatory cytokines are provided herein for use in treating SARS, including SARS-associated coronavirus (SARS-CoV) infection. Inhibitors of TNF are disclosed herein, as is the use of said inhibitors for treating SARS, including SARS-CoV. Methods of identifying and screening for said inhibitors are also provided.
대표청구항▼
What is claimed is: 1. A composition comprising: a therapeutically effective amount of an inhibitor of a SARS-associated inflammatory cytokine in a pharmaceutically acceptable carrier, wherein said therapeutically effective amount of an inhibitor of a SARS-associated inflammatory cytokine in a phar
What is claimed is: 1. A composition comprising: a therapeutically effective amount of an inhibitor of a SARS-associated inflammatory cytokine in a pharmaceutically acceptable carrier, wherein said therapeutically effective amount of an inhibitor of a SARS-associated inflammatory cytokine in a pharmaceutically acceptable carrier is in an amount sufficient to generate a response that reduces the clinical impact of the infection in a SARS patient, additionally comprising an anti-coronaviral compound in the pharmaceutically acceptable carrier, wherein the anti-viral compound is an anti-coronaviral compound. 2. The composition of claim 1, wherein the anti-coronaviral compound is an inhibitor of viral RNA-dependent RNA polymerase, an inhibitor of virus-encoded protease that affects processing of a viral RNA-dependent RNA polymerase, an inhibitor of coronavirus budding or release from infected cells, inhibitor of coronavirus budding or release from infected cells affects the activity of hemagglutinin-esterase, an inhibitor of virus binding to a specific cell surface receptor, an inhibitor of receptor-induced conformational changes in virus spike glycoprotein that are associated with virus entry or combinations thereof. 3. The composition of claim 1, wherein the anti-coronaviral compound is an inhibitor of viral RNA dependent RNA polymerase. 4. A composition comprising: a soluble recombinant SARS-associated inflammatory cytokine receptor, an anti-body to a SARS-associated inflammatory cytokine, a small molecule that affects the activity of a SARS-associated inflammatory cytokine, a SARS-associated antisense oligonucleotide or a combination thereof, additionally comprising an anti-coronviral compound such as an inhibitor of viral RNA- dependent RNA polymerase, an inhibitor of virus-encoded protease that affects processing of a viral RNA-dependent RNA polymerase, an inhibitor of coronavirus budding or release from infected cells such as one that affects the activity of hemagglutinin-esterase, an inhibitor of a virus binding to a specific cell surface receptor, an inhibitor of receptor-induced conformational changes in virus spike glycoprotein that are associated with virus entry or combinations thereof, wherein said components are present in an amount sufficient to generate a response that reduces the clinical impact of the infection in a SARS patient, additionally comprising an inhibitor of viral RNA-dependent RNA polymerase, an inhibitor of a virus-encoded protease that affects processing of a viral RNA-dependent RNA polymerase, an inhibitor of coronavirus budding or release from infected cells, inhibitor of coronavirus budding or release from infected cells affects the activity of hemagglutinin-esterase, an inhibitor of virus binding to a specific cell surface receptor, an inhibitor of receptor-induced conformational changes in virus spike glycoprotein that are associated with virus entry or combinations thereof. 5. A composition comprising: a first substance selected from the group consisting of a soluble recombinant TNF receptor, an antibody to TNF, a small molecule that affects the activity of a TNF, a TNF antisense oligonucleotide and combinations thereof; and a second substance up consisting of an anti-coronaviral compound selected from the group consisting of an inhibitor of viral RNA-dependent RNA polymerase, an inhibitor of virus-encoded protease that affects processing of a viral RNA-dependent RNA polymerase, an inhibitor of coronavirus budding or release from infected cells such as one that affects the activity of hemagglutinin-esterase, an inhibitor of a virus binding to a specific cell surface receptor, an inhibitor of receptor-induced conformational changes in virus spike glycoprotein that are associated with virus entry or combinations thereof, wherein said components are present in an amount sufficient to generate a response that reduces the clinical impact of the infection in a SARS patient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (33)
Le Junming ; Vilcek Jan ; Daddona Peter ; Ghrayeb John ; Knight David ; Siegel Scott, Anti-TNF antibodies and peptides of human tumor necrosis factor.
Baker Brenda F. ; Bennett C. Frank ; Butler Madeline M. ; Shanahan ; Jr. William R., Antisense oligonucleotide modulation of tumor necrosis factor-.alpha. (TNF-.alpha.) expression.
Crimmin Michael John (Cowley GB3) Galloway William Alan (Cowley GB3) Gearing Andrew John Hubert (Cowley GB3), Inhibition of TNF production with matrix metaloproteinase inhibitors.
Mandell Gerald L. (Earlysville VA) Sullivan Gail W. (Charlottesville VA) Novick William J. (Lebanon NJ), Method of inhibiting the activity of leukocyte derived cytokines.
Mandell Gerald L. (Earlysville VA) Sullivan Gail W. (Charlottesville VA) Novick William J. (Lebanon NJ), Method of inhibiting the activity of leukocyte derived cytokines.
Le Junming (Jackson Heights NY) Vilcek Jan (New York NY) Dadonna Peter (Palo Alto CA) Ghrayeb John (Thorndale PA) Knight David (Berwyn PA) Siegel Scott A. (Westborough MA), Methods of treating TNF-a
상세보기
Eberle Josef (Munich DEX) Seibl Rudolf (Penzberg DEX) Kessler Christoph (Dorfen DEX) Konig Bernhard (Berg DEX), Reagents and kits for determining polymerase activity.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.